Phase I Combination Study of Deforolimus (Ridaforolimus/MK8669) and MK0646 in Patients With Advanced Cancer.

Trial Profile

Phase I Combination Study of Deforolimus (Ridaforolimus/MK8669) and MK0646 in Patients With Advanced Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Jun 2015

At a glance

  • Drugs Dalotuzumab (Primary) ; Ridaforolimus (Primary)
  • Indications Cancer; Colorectal cancer; Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 28 Sep 2010 Planned end date changed from Feb 2011 to Nov 2011 as reported by ClinicalTrials.gov.
    • 21 May 2010 Results will be presented at the American Society of Clinical Oncology Annual Meeting 2010, according to an Ariad Pharmaceuticals media release.
    • 31 Mar 2010 Planned number of patients changed from 50 to 87 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top